Boehringer Corp_build

Boehringer Ingelheim has started patient enrolment in its large-scale Dynagito study to treat chronic obstructive pulmonary disease (COPD).

The trial is designed to evaluate the potential benefit of tiotropium + olodaterol Respimat FDC compared to Spiriva (tiotropium) Respimat on reducing the risk of sudden worsening of symptoms (exacerbations) and improving survival in these patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Spiriva is the most prescribed COPD maintenance therapy across the world and its position is supported by proven clinical efficacy in reducing the risk of COPD exacerbations and improving lung function, improving quality of life in COPD patients and positive long term experience across all COPD severities.

"In severe cases, exacerbations even increase the risk of death. Therefore, there is an ongoing need to optimise the effect of treatment in reducing the risk of exacerbations in COPD."

University of Liverpool professor of Pulmonary and Rehabilitation Medicine and lead study investigator Peter Calverley said: "Exacerbations not only worsen the lung function of COPD patients and often lead to hospitalisation, they also have a significant impact on patients’ overall wellbeing.

"In severe cases, exacerbations even increase the risk of death. Therefore, there is an ongoing need to optimise the effect of treatment in reducing the risk of exacerbations in COPD."

Around 7,800 patients in 59 countries will be enrolled in the 52-week multi-national double-blind trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will investigate the impact of once daily, orally inhaled tiotropium + olodaterol Respimat FDC (5/5µg) compared to Spiriva Respimat monotherapy (5µg) on exacerbations in patients with severe to very severe COPD.

Calverley noted: "The value of tiotropium in reducing the risk of exacerbations is well known. Data from the TONADO studies suggest that tiotropium + olodaterol Respimat may reduce the risk of exacerbations even further than tiotropium alone.

"We look forward to further evaluating the effect of this potential new treatment on exacerbations in a dedicated exacerbation study."

According to the company, results from the trial are expected to be reported in 2017.

The Dynagito trial is part of the TOviTO clinical trial programme for tiotropium + olodaterol Respimat FDC.

Image: Boehringer Ingelheim’s corporate headquarters in Ingelheim, Germany. Photo: courtesy of Boehringer Ingelheim GmbH.